Published online 25 August 2008
Haematologica, Vol 93, Issue 11, 1739-1742 doi:10.3324/haematol.13204
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tricot, G.
Right arrow Articles by Cottler-Fox, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tricot, G.
Right arrow Articles by Cottler-Fox, M.

Brief Reports

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

Guido Tricot1, Bart Barlogie2, Maurizio Zangari2, Frits van Rhee2, Antje Hoering3, Jackie Szymonifka3, Michele Cottler-Fox4

1 Division of Hematology and Blood and Bone Marrow Transplantation, University of Utah School of Medicine, Salt Lake City, UT
2 The Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR
3 The Cancer Research and Biostatistics, Seattle, WA and
4 Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Correspondence: Guido Tricot, MD, PhD, The University of Utah School of Medicine, 30N 1900E, 5C402,Salt Lake City, UT 84132 USA. E-mail:guido.tricot{at}hsc.utah.edu

ABSTRACT

Quality and quantity of mobilized peripheral blood stem cells determine the safety of tandem autologous transplants in myeloma. Using the same mobilization chemotherapy with DT-PACE in two consecutive protocols, robustness of stem cell collection and rapidity of engraftment after transplantation were assessed. We employed either twice a day filgrastim versus two doses of pegfilgrastim. Advantages of pegfilgrastim were: (i) a higher percentage of patients collected 15x106/kg in the first three days (p<0.001); (ii) the median number of CD34 cells/kg collected on day 1 was higher (p=0.004); (iii) the median number of growth factor injections was 2 versus 26 (p<0.0001); (iv) post-transplantation neutrophil recovery was faster after first and second transplant (p<0.001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization.

Key words: stem cells, mobilization, myeloma, pegfilgrastim.